About the Authors
Rheumatic Diseases Unit, University of Edinburgh, Western General Hospital Edinburgh, Edinburgh, United Kingdom
Department of Medicine and Therapeutics, University of Aberdeen Medical School, Aberdeen, United Kingdom
Department of Internal Medicine, Erasmus MC, Rotterdam, Netherlands
Department of Internal Medicine, University of Florence, Florence, Italy
Department of Genetics, University of Barcelona, Barcelona, Spain
Department of Endocrinology, Aarhus Sygehus, Aarhus, Denmark
Institute for Research in Extramural Medicine, VU University Medical Center, Amsterdam, Netherlands
Department of Biochemistry and Experimental Medicine, The Children's Memorial Health Institute, Warsaw, Poland
Department of Endocrinology and Nuclear Medicine, University of Graz, Graz, Austria
Strangeways Research Laboratory, Cambridge University, Cambridge, United Kingdom
Oxagen Limited, Abingdon, United Kingdom
Hospital del Mar-IMIM, Universitat Autònoma de Barcelona, Barcelona, Spain
Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine and Biomedical Research Institute, Foundation for Research and Technology-Hellas, Ioannina, Greece
SHR, AGU, HAPP, and JPTMvL hold patents on the use of various genetic markers for the diagnosis of osteoporosis, including the COLIA1 Sp1 polymorphism.
Author contributions and additional contributors are listed at the end of this paper.